CTOR
Citius Oncology, Inc.
NASDAQ: CTOR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$0.88
+2.31% today
Updated 2026-04-30
Market cap
$77.43M
P/E ratio
—
P/S ratio
19.63x
EPS (TTM)
$-0.31
Dividend yield
—
52W range
$0 – $6
Volume
0.3M
Citius Oncology, Inc. (CTOR) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| R&D | — | $6.86M | $4.24M | $4.92M | $6.42M |
| SG&A | — | $2.86M | $7.88M | $15.65M | $17.10M |
| Operating income | — | $-9.71M | $-12.12M | $-20.57M | $-23.52M |
| Operating margin | — | — | — | — | — |
| EBITDA | $-10110.00 | $-4.86M | $-12.12M | $-20.57M | $-23.49M |
| EBITDA margin | — | — | — | — | — |
| EBIT | — | $-4.86M | $-12.12M | $-20.57M | — |
| Interest expense | — | — | — | $0.00 | $218032.00 |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-10113.00 | $-10.87M | $-12.70M | $-21.15M | $-24.76M |
| Net income growth (YoY) | — | -107337.9% | -16.9% | -66.6% | -17.1% |
| Profit margin | — | — | — | — | — |